MX2009005358A - Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. - Google Patents

Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.

Info

Publication number
MX2009005358A
MX2009005358A MX2009005358A MX2009005358A MX2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A
Authority
MX
Mexico
Prior art keywords
sulfanylmethyl
pyrazolo
pyrimidin
derivatives
cxcr2 antagonists
Prior art date
Application number
MX2009005358A
Other languages
English (en)
Inventor
Neil John Press
Simon James Watson
Carsten Spanka
David Porter
Peter Hunt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005358A publication Critical patent/MX2009005358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y al uso de estos compuestos como farmacéuticos, por ejemplo para prevenir o tratar un padecimiento o enfermedad mediado por el receptor CXCR2.
MX2009005358A 2006-11-23 2007-11-21 Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. MX2009005358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124682 2006-11-23
PCT/EP2007/062662 WO2008062026A1 (en) 2006-11-23 2007-11-21 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists

Publications (1)

Publication Number Publication Date
MX2009005358A true MX2009005358A (es) 2009-06-05

Family

ID=37891755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005358A MX2009005358A (es) 2006-11-23 2007-11-21 Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.

Country Status (10)

Country Link
US (1) US20100152205A1 (es)
EP (1) EP2094697A1 (es)
JP (1) JP2010510291A (es)
KR (1) KR20090082424A (es)
CN (1) CN101573359A (es)
AU (1) AU2007324472A1 (es)
BR (1) BRPI0718956A2 (es)
CA (1) CA2669579A1 (es)
MX (1) MX2009005358A (es)
WO (1) WO2008062026A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
US10301378B2 (en) 2013-06-18 2019-05-28 New York University Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets
CN104086561A (zh) * 2014-07-08 2014-10-08 国家纳米科学中心 一种具有高填充因子的可溶性有机光伏小分子材料、制备方法及其用途
AU2017319500C1 (en) 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation

Also Published As

Publication number Publication date
JP2010510291A (ja) 2010-04-02
AU2007324472A1 (en) 2008-05-29
BRPI0718956A2 (pt) 2013-12-17
CA2669579A1 (en) 2008-05-29
KR20090082424A (ko) 2009-07-30
CN101573359A (zh) 2009-11-04
US20100152205A1 (en) 2010-06-17
WO2008062026A1 (en) 2008-05-29
EP2094697A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
EA201070091A1 (ru) Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
CR9389A (es) Compuestos de imidazopiridazina
UA97794C2 (ru) Цитотоксические агенты, которые включают производные томаймицина, и их терапевтическое применение
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2009006860A (es) Derivados de 2-aza-biciclo[3.1.0]hexano como antagonistas del receptor orexina.
PL2164847T3 (pl) Związki 3-azabicyklo[3.3.0]oktanowe
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
WO2006044449A3 (en) Cgrp receptor antagonists
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal